Rashmi Chandra

Nanoparticle drug delivery systems have evolved as a revolutionary approach to the treatment of cardiovascular diseases (CVDs). These systems present a highly hopeful alternative to traditional drugs, which often have limited bioavailability, systemic toxicity, poor solubility, and a dearth of targeted therapeutic effect. Liposomal, polymeric, metallic, and dendrimer-based nanoparticles are just a few examples of nanoscale carriers that can deliver drugs to injured tissues in a targeted fashion. This facilitates controlled and sustained drug release while at the same time reducing off-targeting effects. Nanotechnology can potentially enhance therapeutic responses significantly by aiding in the stabilization of medication, circulation time, and cellular internalization. This, in turn, will help to reduce unwanted effects and enhance patient care. The application of nanoparticles in tissue engineering is not only limited to the delivery of drugs but also plays a critical role in the regeneration of heart tissue and function as good contrast agents for imaging purposes, allowing for real-time monitoring of diseases. However, despite their enormous promise, their widespread clinical use is hampered by obstacles such as the toxicity of nanoparticles, the quick clearance of the immune system, intricacy of manufacture on a large scale, and onerous regulatory approval procedures. The effective integration of nanoparticle therapeutics with traditional cardiovascular treatment will depend upon the successful solution of these issues through the creation of biocompatible materials, effective surface modifications, and scalable manufacturing processes. Under the purview of this research, the latest advances in drug delivery through nanotechnology are explored, the mechanisms by which therapeutic action is enhanced are explored, and the potential future directions for implementing these advances into cardiovascular therapy protocols are explored.